Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients.
暂无分享,去创建一个
D. Wendum | J. Molina | K. Lacombe | L. Serfaty | J. Guéchot | P. Girard | P. Bonnard | C. Lascoux-Combe | J. Bottero | P. Miailhes
[1] F. Carrat,et al. How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: the area under the ROC curve revisited. , 2008, Clinical chemistry.
[2] D. Neau,et al. Validation and Comparison of Simple Noninvasive Indexes for Predicting Liver Fibrosis in HIV-HCV-Coinfected Patients: ANRS CO3 Aquitaine Cohort , 2008, The American Journal of Gastroenterology.
[3] Y. Ngo,et al. An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load , 2008, PloS one.
[4] F. Carrat,et al. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study--ANRS HC02. , 2008, Journal of hepatology.
[5] Patrice Cacoub,et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease , 2007, BMC gastroenterology.
[6] V. de Lédinghen,et al. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. , 2007, Clinical chemistry.
[7] Patrice Faure,et al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. , 2007, Journal of hepatology.
[8] V. Soriano,et al. Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. , 2007, The Journal of infectious diseases.
[9] V. Paradis,et al. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. , 2007, Journal of hepatology.
[10] F. Roudot-thoraval,et al. Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines? , 2007, Journal of hepatology.
[11] S. Pol,et al. Liver‐related mortality in human‐immunodeficiency‐virus‐infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study) * , 2007, Journal of viral hepatitis.
[12] A. Alberti,et al. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. , 2007, World journal of gastroenterology.
[13] D. Capron,et al. Noninvasive diagnosis of liver fibrosis by ultrasonic transient elastography (Fibroscan) , 2006, European journal of gastroenterology & hepatology.
[14] J. Montaner,et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.
[15] V. Soriano,et al. Management of chronic hepatitis B and C in HIV-coinfected patients. , 2006, The Journal of antimicrobial chemotherapy.
[16] S. Lipshultz,et al. Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis. , 2006, Atherosclerosis.
[17] F. Carrat,et al. Hepatic steatosis in HIV–HCV coinfected patients: analysis of risk factors , 2006, AIDS.
[18] F. Carrat,et al. Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV , 2006, AIDS.
[19] F. Oberti,et al. A novel panel of blood markers to assess the degree of liver fibrosis , 2005, Hepatology.
[20] Lungen Lu,et al. Prediction of significant fibrosis in HBeAg‐positive patients with chronic hepatitis B by a noninvasive model , 2005, Hepatology.
[21] J. Kench,et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. , 2005, Clinical chemistry.
[22] J. Macías,et al. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes , 2005, Gut.
[23] Albert Tran,et al. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus , 2005, Comparative hepatology.
[24] N. Afdhal,et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. , 2005, Journal of hepatology.
[25] R. Gandhi. Guideline watch. New guidelines on treating chronic hepatitis B and C in HIV-coinfected patients. , 2005, AIDS Clinical Care.
[26] V. Wong,et al. Identification of Chronic Hepatitis B Patients without Significant Liver Fibrosis by a Simple Noninvasive Predictive Model , 2005, American Journal of Gastroenterology.
[27] Thomas K. Hazlet,et al. Global Epidemiology of Hepatitis B Virus , 2004, Journal of clinical gastroenterology.
[28] D. Thabut,et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C , 2004, Comparative hepatology.
[29] D. Ganem,et al. Hepatitis B virus infection--natural history and clinical consequences. , 2004, The New England journal of medicine.
[30] J. Kalbfleisch,et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C , 2003, Hepatology.
[31] T. Poynard,et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. , 2003, Journal of hepatology.
[32] R. Testa,et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. , 2003, Archives of internal medicine.
[33] Llorenç Quintó,et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model , 2002, Hepatology.
[34] E. Schiff,et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection , 2002, American Journal of Gastroenterology.
[35] J. Phair,et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS) , 2002, The Lancet.
[36] R. Paredes,et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[37] T. Poynard,et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study , 2001, The Lancet.
[38] F. Donato,et al. Mortality for liver disease in patients with HIV infection: a cohort study. , 2000, Journal of acquired immune deficiency syndromes.
[39] M. Manns,et al. Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. , 1997, Journal of hepatology.
[40] P. Bedossa,et al. An algorithm for the grading of activity in chronic hepatitis C , 1996, Hepatology.
[41] A. Pesce,et al. Circulating anticoagulant in patients seropositive for human immunodeficiency virus. , 1989, American Journal of Medicine.
[42] J. Hanley,et al. Statistical Approaches to the Analysis of Receiver Operating Characteristic (ROC) Curves , 1984, Medical decision making : an international journal of the Society for Medical Decision Making.
[43] J. R. Landis,et al. The measurement of observer agreement for categorical data. , 1977, Biometrics.
[44] B. Balkau,et al. Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. , 1994, Journal of hepatology.